NVO - Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand | Benzinga
Maker of ‘miracle’ weight loss drugs Ozempic and Wegovy, Novo Nordisk A/S (NYSE:NVO) has announced the acquisition of three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition is part of a larger deal where Novo Holdings is set to acquire Catalent, Inc. (NYSE:CTLT), a global contract development and manufacturing organization.
What Happened: As announced in a press release on Monday, Novo Nordisk’s acquisition of the fill-finish sites from Novo Holdings will enable it to expand its manufacturing capacity for diabetes and obesity treatments.
The three sites, located in Anagni, Italy, Brussels, Belgium, and Bloomington, Indiana, specialize in the sterile filling of drugs. They currently employ over 3,000 people and have ongoing collaborations with Novo Nordisk.
See Also: Why Is Twist Bioscience Stock Trading Higher Today?
Novo Nordisk’s acquisition of the sites is expected to increase its filling capacity ...